We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Omega Diagnostics Group Plc | LSE:ODX | London | Ordinary Share | GB00B1VCP282 | ORD 4P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 2.20 | 2.00 | 2.40 | - | 0.00 | 01:00:00 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
0 | 0 | N/A | 0 |
Date | Subject | Author | Discuss |
---|---|---|---|
29/10/2020 14:59 | He nearly blurted it out but then CK bit his tongue. He did not address it again but clear to me that talks of some sort whether customer or other, are underway | carlisle44 | |
29/10/2020 14:52 | C44 I didnt catch who the mystery person was he very briefly mentioned and discounted to talk about later? | ant15 | |
29/10/2020 14:39 | Searcher0 try listing attentively to yesterday's presentation. Just saying doesn't cut it | carlisle44 | |
29/10/2020 13:49 | SEARCHER0 Completely discounted by their CFO in the presentation have sufficient cash to do everything including further factory space and new machinery through to April They are trading profitably but with the new capacity and production will be making substantial profits in The New Year. | ant15 | |
29/10/2020 13:49 | Presumably you missed the presentation yesterday where this was explicitly answered? Just saying. | coley15 | |
29/10/2020 13:44 | Feels like a placing in the works or a seller the way the share price is pinned here. They may need it to take on the very larger orders. Just saying. | searcher0 | |
29/10/2020 13:33 | A rather nice new tweet direct from ODX - with a chart showing capacity increasing to 2m lateral flow tests per week by April: "Omega Diagnostics @OmegaDiagnostic ยท 32m By end of 2020 we will have production capacity at our Alva site for 0.5m lateral flow tests a week to match expected demand: ✅ 200k tests a week min for AbC-19 Rapid Tests ✅ some CD4 test production ✅ the rest for Mologic antibody and antigen test production | rivaldo | |
29/10/2020 12:20 | looks like someone has sold. | thehitman1 | |
29/10/2020 12:15 | We need a couple of institutions on board.i cant see the price doing much now until the next update which is now a few months away. | upomega | |
29/10/2020 12:04 | Not sure if this has already been posted.https://www.h | xtrmntr | |
29/10/2020 11:54 | The MM's must have quite a few shares to move...hopefully we will start to tick up this afternoon.... | barrywhit | |
29/10/2020 09:24 | walking it back up now | thehitman1 | |
29/10/2020 09:21 | lots of buys today. | thehitman1 | |
29/10/2020 08:59 | Link to the Investor Presentation in the tweet: | barrywhit | |
29/10/2020 08:36 | Looking further ahead, Mr Harbinson said staff numbers could double again to 200 if there is deemed to be sufficient demand for its test kits. Omega hopes to have further clarity on those demand levels by the end of this year. READ MORE: Omega confirms Covid-19 test order volumes “We are exploring how we might take production up to the order of two million tests per week,” he said. “If we were doing that I think we would be looking to mid-April as a timeframe.” Shares in AIM-listed Omega fell yesterday after the company revealed a 29 per cent drop in turnover for the first six months of the year. The expected decline in revenues to just less than £3.2m was driven by a 38% fall in its dominant food intolerance testing division, which suffered as global health priorities focused on the pandemic. As a result, earnings for the period – as calculated before interest, tax, depreciation and amortisation – will come in at a loss of approximately £1.3m. Mr Harbinson said there has since been a recovery in demand for food intolerance testing, with a rebound in orders coming from across Europe, the Middle East and Latin America. Sales in October are expected to be approximately 20% higher on the same period last year. READ MORE: Full launch this month as Omega gets Covid test approval Omega said it believes there are significant near-term opportunities for this business unit in China, where it is awaiting confirmation of regulatory approval of a self-test version of its Food Detective kit. The company is also looking to access the US market. Earlier this month, the UK Rapid Test Consortium (UK-RTC) of which Omega is a member announced the UK Government had placed its first order for one million rapid AbC-19 antibody tests, which detect whether an individual has been previously infected by the coronavirus. Omega will manufacture approximately 175,000 of the first one million tests, and will produce “not less” than 25% of the demand from total orders placed over the term of the Government supply agreement. The company is also working on a rapid antibody test with Bedfordshire-based Mologic, as well as a rapid antigen test to detect those currently infected by the coronavirus. Both are lateral flow tests – similar to a home pregnancy test – which produce immediate results at the point where the test is taken. READ MORE: Omega Diagnostics gets key clearance for HIV tests The Mologic antibody test is said to be gaining “early sales traction” that “provides confidence for performance in the second half of the year”. A prototype of the Mologic antigen test is currently in evaluation “in a number of healthcare settings”, with the results to date looking “promisingR By contrast, the Mologic ELISA antibody test, which must be sent away to a lab to procure results, has failed to gain the levels of traction initially anticipated. Mr Harbinson said it appears to be getting “squeezed out” between similar lab tests from larger competitors that can run on much higher volume equipment, and a broader market preference for lateral flow tests that produce fast results. As a “mitigating strategy”, Omega is looking at whether to offer its ELISA test to healthcare practitioners in the UK, with the results processed at its laboratory in Littleport, Cambridgeshire. Elsewhere, the company has received a number of purchase orders from Uganda and Mozambique for its Visitect CD4 test to help manage the care of patients with HIV. These have been channelled through a supply agreement signed earlier this year with the Clinton Health Access Initiative. Omega will announce its half-year results on November 30. Its shares closed yesterday’s trading down 18.5p at 74p. | barrywhit | |
29/10/2020 08:30 | Looks like some interesting stuff in this new article from Scotland - I've reached my free article limit, so maybe someone else could post the rest? "3 hrs ago Omega adds staff at its Alva HQ as Covid test production gears up Omega Diagnostics has boosted headcount at its facility in Alva by more than two-thirds as the Scottish diagnostics specialist has geared up for mass production of Covid-19 testing kits. Speaking after the company released a trading update covering the six months to September 30, group finance director Kieron Harbinson said the Alva headquarters will be home to more than 100 employees from the start of next week. The increase from 60 in May follows a £1 million investment to increase its high-volume manufacturing capability, with current capacity of 200,000 tests per week set to rise to 500,000 by the end of December." | rivaldo | |
29/10/2020 08:20 | everyone topping up today. | thehitman1 | |
29/10/2020 08:18 | Bought some more after yesterday's presentation | teamwork1 | |
29/10/2020 07:37 | Impressively confident presentation - and great to hear that ODX are fully funded for the development of production capacity to 2m a week and more.... | rivaldo | |
29/10/2020 07:18 | Timmmmbeeeeeerrrr 0.2 placing at 8am | charle8888 | |
29/10/2020 01:44 | not idiots, shorters and the same individual. | thehitman1 | |
29/10/2020 01:00 | Hopefully they will last longer than spivs before them. | upomega |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions